Medicover AB (publ)

LSE:0RPS Stock Report

Market Cap: SEK 37.7b

Medicover Valuation

Is 0RPS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RPS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 545.77
Fair Value
54.3% undervalued intrinsic discount
6
Number of Analysts

Below Fair Value: 0RPS (SEK249.5) is trading below our estimate of fair value (SEK545.77)

Significantly Below Fair Value: 0RPS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RPS?

Key metric: As 0RPS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0RPS. This is calculated by dividing 0RPS's market cap by their current earnings.
What is 0RPS's PE Ratio?
PE Ratio112.8x
Earnings€30.60m
Market Cap€3.45b

Price to Earnings Ratio vs Peers

How does 0RPS's PE Ratio compare to its peers?

The above table shows the PE ratio for 0RPS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23.3x
IDHC Integrated Diagnostics Holdings
9.7x20.03%US$209.3m
KOO Kooth
5.9x-24.07%UK£47.8m
CVSG CVS Group
46.2x20.79%UK£895.3m
SPI Spire Healthcare Group
31.5x23.52%UK£800.7m
0RPS Medicover
112.8x29.14%SEK 37.7b

Price-To-Earnings vs Peers: 0RPS is expensive based on its Price-To-Earnings Ratio (112.8x) compared to the peer average (23.3x).

Price to Earnings Ratio vs Industry

How does 0RPS's PE Ratio compare vs other companies in the European Healthcare Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0RPS 112.8xIndustry Avg. 19.4xNo. of Companies6PE01020304050+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0RPS is expensive based on its Price-To-Earnings Ratio (112.8x) compared to the European Healthcare industry average (19.4x).

Price to Earnings Ratio vs Fair Ratio

What is 0RPS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RPS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio112.8x
Fair PE Ratio54.8x

Price-To-Earnings vs Fair Ratio: 0RPS is expensive based on its Price-To-Earnings Ratio (112.8x) compared to the estimated Fair Price-To-Earnings Ratio (54.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RPS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 249.50
SEK 240.82
-3.48%
13.86%SEK 286.50SEK 207.80n/a6
May ’26SEK 241.88
SEK 220.11
-9.00%
4.49%SEK 237.92SEK 208.53n/a6
Apr ’26SEK 199.60
SEK 215.84
+8.14%
3.26%SEK 228.21SEK 206.85n/a6
Mar ’26SEK 209.01
SEK 216.88
+3.77%
6.56%SEK 235.72SEK 188.81n/a6
Feb ’26SEK 207.50
SEK 214.74
+3.49%
7.24%SEK 236.52SEK 189.93n/a5
Jan ’26SEK 192.00
SEK 214.52
+11.73%
9.40%SEK 239.18SEK 178.92n/a5
Dec ’25SEK 177.00
SEK 214.38
+21.12%
10.25%SEK 239.13SEK 178.89n/a4
Nov ’25SEK 182.00
SEK 216.22
+18.80%
10.28%SEK 240.78SEK 180.11n/a4
Oct ’25SEK 186.00
SEK 212.20
+14.09%
9.68%SEK 237.74SEK 180.47n/a4
Sep ’25SEK 190.40
SEK 205.30
+7.83%
8.82%SEK 220.21SEK 179.80n/a3
Aug ’25SEK 188.80
SEK 207.63
+9.98%
9.31%SEK 222.20SEK 180.31n/a3
Jul ’25SEK 193.00
SEK 195.12
+1.10%
8.23%SEK 211.95SEK 173.48n/a3
Jun ’25SEK 195.80
SEK 199.13
+1.70%
8.22%SEK 220.14SEK 180.18n/a3
May ’25SEK 171.88
SEK 199.13
+15.86%
8.22%SEK 220.14SEK 180.18SEK 241.883
Apr ’25SEK 138.00
SEK 190.26
+37.87%
5.37%SEK 203.56SEK 178.75SEK 199.603
Mar ’25SEK 142.49
SEK 190.26
+33.53%
5.37%SEK 203.56SEK 178.75SEK 209.013
Feb ’25SEK 170.30
SEK 201.25
+18.18%
8.99%SEK 220.52SEK 171.59SEK 207.504
Jan ’25SEK 150.43
SEK 201.25
+33.78%
8.99%SEK 220.52SEK 171.59SEK 192.004
Dec ’24SEK 141.97
SEK 213.90
+50.67%
10.55%SEK 236.19SEK 177.15SEK 177.004
Nov ’24SEK 127.24
SEK 223.16
+75.39%
10.99%SEK 248.27SEK 183.14SEK 182.004
Oct ’24SEK 143.96
SEK 223.16
+55.02%
10.99%SEK 248.27SEK 183.14SEK 186.004
Sep ’24SEK 155.95
SEK 223.16
+43.10%
10.99%SEK 248.27SEK 183.14SEK 190.404
Aug ’24SEK 159.55
SEK 219.66
+37.67%
10.53%SEK 240.64SEK 180.48SEK 188.804
Jul ’24SEK 160.87
SEK 224.27
+39.41%
11.97%SEK 251.43SEK 179.69SEK 193.004
Jun ’24SEK 166.89
SEK 219.29
+31.39%
10.76%SEK 244.17SEK 180.49SEK 195.804
May ’24SEK 169.35
SEK 214.01
+26.37%
9.67%SEK 232.10SEK 179.95SEK 171.884
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
SEK 240.82
Fair Value
3.6% overvalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/19 10:42
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medicover AB (publ) is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
null nullABG Sundal Collier Sponsored
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB